Research & Development
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Disc Sees Promise In Hematology With Former Roche Schizophrenia Candidate
Phase II data in two rare hematological disorders show potential for transformative therapeutic benefit, according to analysts. The company awaits more results for further confirmation.
Pipeline Watch: ASCO Readouts Dominate
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ’s Danicopan Could Protect Ultomiris After Pivotal Combination Success In PNH
The major’s factor D inhibitor has increased hemoglobin in a subset of paroxysmal nocturnal hemoglobinuria patients when added to a C5 inhibitor, paving the way for an approval that could help protect Ultomiris from competition.
Chinese Language Podcast: ASCO专集
J&J and Legend’s Carvykti shines at ASCO while Junshi provides PD-1 antibody toripalimab updates. Alongside, ADCs from Biokin, BlissBio also steps into the spotlight. Guest speaker Leon Tang in the US, Brian Yang in Beijing and Dexter Yan in Shanghai discuss what stands out in this special ASCO episode of the latest Chinese-language podcast.
Regeneron’s Libtayo/Fianlimab LAGs Bristol’s Opdualag On Timing, But May Win On Efficacy
The PD-1/LAG-3 combination showed a high response rate in a small number of melanoma patients with prior PD-1 exposure.
Shionogi Renews 10-Year Goal After Infectious Disease Success
Shionogi renews its 10-year strategic plan originally announced in 2020 following the successful debut of COVID-19 therapeutic Xocova. Fulfilling its 2025 goals earlier, its new strategy covers HIV and COVID-19 products with more new products to be launched.
Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy
The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.
FibroGen Misses In First Of Two Pivotal DMD Trials
The biotech’s pamrevlumab fails a Phase III study in non-ambulatory Duchenne muscular dystrophy, but the antibody still has a shot in ambulatory DMD, as well as IPF and pancreatic cancer.
Regeneron, Pfizer Tout Potential BCMA Bispecific Advantages At ASCO
Regeneron presented data for linvoseltamab, while Pfizer presented data for elranatamab, including in patients who previously received BCMA-directed therapy.
Pipeline Watch: 11 Approvals And 12 Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
ASCO 2023 – Novartis’s Adjuvant Breast Cancer Win Comes With Caveats
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.
ASCO 2023 – Roche Sees Morpheus And Takes The Red Pill
The company’s TIGIT data are strong enough for a phase 3 trial to be launched, ASCO learns.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.